Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Short-term Investments (2016 - 2025)

Amicus Therapeutics filings provide 16 years of Short-term Investments readings, the most recent being $79.5 million for Q4 2025.

  • On a quarterly basis, Short-term Investments rose 119.72% to $79.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $79.5 million, a 119.72% increase, with the full-year FY2025 number at $79.5 million, up 119.72% from a year prior.
  • Short-term Investments hit $79.5 million in Q4 2025 for Amicus Therapeutics, up from $73.3 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $237.3 million in Q4 2021 to a low of $16.1 million in Q3 2024.
  • Median Short-term Investments over the past 5 years was $75.2 million (2022), compared with a mean of $102.1 million.
  • Biggest five-year swings in Short-term Investments: tumbled 77.98% in 2023 and later soared 354.93% in 2025.
  • Amicus Therapeutics' Short-term Investments stood at $237.3 million in 2021, then tumbled by 38.99% to $144.8 million in 2022, then plummeted by 72.92% to $39.2 million in 2023, then fell by 7.68% to $36.2 million in 2024, then skyrocketed by 119.72% to $79.5 million in 2025.
  • The last three reported values for Short-term Investments were $79.5 million (Q4 2025), $73.3 million (Q3 2025), and $72.3 million (Q2 2025) per Business Quant data.